No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.
UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.
A new report from the European Centre for Disease Prevention and Control indicates that universal immunization of newborns against respiratory syncytial virus could significantly reduce infant hospitalizations across the EU. The findings come as the RSV season approaches, with evidence showing national programs using nirsevimab or maternal vaccination are associated with large reductions in infant hospitalizations.
A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.
The European Commission accepted Sanofi's commitments to end an antitrust investigation into allegations the company disparaged CSL Seqirus' competing flu vaccine. The commitments will become legally binding for Sanofi, allowing it to avoid a fine.
Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.
Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.
The FDA has approved Sanofi's Sarclisa (isatuximab) for subcutaneous delivery via a wearable on-body injector, marking the first cancer drug to receive approval for this delivery method. The device offers multiple myeloma patients a less burdensome alternative to intravenous infusions.